Security
White River Energy Corp · WTRV
WTRVOTCCommon stockCurrentCIK 1860657Updated Oct 12, 2026
WTRV price & chart
Loading TradingView…
OTC:WTRV on TradingView ↗About the company
Allarity Therapeutics, Inc. (NASDAQ: ALLR) is a clinical-stage pharmaceutical company focused on developing personalized cancer treatments. The Company is developing stenoparib, a novel PARP/tankyrase inhibitor for patients with advanced ovarian cancer, and is using its proprietary DRP® technology to develop a companion diagnostic designed to identify patients expected to derive the greatest clinical benefit from stenoparib. Allarity’s principal operations are located in Denmark, and its U.S. business address is in Florida. For more information, visit www.allarity.com.
In the news
No coverage from other publishers is available.
Recent filings
Other Events
Items 8.01, 9.01
Other Events
Items 8.01, 9.01
Other Events
Items 8.01, 9.01
Other Events
Items 8.01, 9.01
Results of Operations and Financial Condition
Items 2.02, 9.01
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 18,258,000Source | 22,650,000Source | 11,862,000Source | 14,544,000Source |
| Property, Plant and Equipment, NetUSD | 330,000Source | 309,000Source | 20,000Source | 21,000Source |
| Intangible Assets, Net (Excluding Goodwill)USD | — | 0Source | — | 9,549,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 14,687,000Source | 19,533,000Source | 166,000Source | — |
| Assets, CurrentUSD | 17,928,000Source | 22,341,000Source | 1,971,000Source | 4,968,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 8,430,000Source | 10,839,000Source | 14,613,000Source | 12,654,000Source |
| Stockholders’ equity: | ||||
| Preferred Stock, Value, IssuedUSD | — | 0Source | 1,742,000Source | 2,000Source |
| Common Stock, Value, IssuedUSD | 3,000Source | 1,000Source | — | 2,000Source |
| Additional Paid in CapitalUSD | 144,233,000Source | 131,130,000Source | 90,369,000Source | 83,156,000Source |
| Retained Earnings (Accumulated Deficit)USD | -130,197,000Source | -118,966,000Source | -94,451,000Source | -82,550,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -1,021,000Source | -354,000Source | -411,000Source | -721,000Source |
| Stockholders' Equity Attributable to ParentUSD | 9,828,000Source | 11,811,000Source | -2,751,000Source | -113,000Source |
| Liabilities and EquityUSD | 18,258,000Source | 22,650,000Source | 11,862,000Source | 14,544,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 8,430,000Source | 10,839,000Source | 14,167,000Source | 11,222,000Source |
| Operating Lease, Liability, CurrentUSD | — | — | — | 8,000Source |
| Accounts Payable, CurrentUSD | 4,282,000Source | 4,182,000Source | 8,416,000Source | 6,251,000Source |
| Deferred Income Tax Liabilities, NetUSD | — | 0Source | 446,000Source | 349,000Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 2,667,000Source | 5,232,000Source | 1,309,000Source | 1,904,000Source |
| Deferred Tax Liabilities, NetUSD | 0Source | 0Source | 446,000Source | 349,000Source |
| Long-term DebtUSD | — | — | — | 2,644,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | -16,058,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | — | 9,000Source | 37,000Source | 60,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 482,000Source | 71,000Source | -71,000Source | 1,752,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts PayableUSD | -1,139,000Source | -4,108,000Source | 2,165,000Source | 6,207,000Source |
| Deferred Income Tax Expense (Benefit)USD | 0Source | -381,000Source | 97,000Source | -1,612,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -14,820,000Source | -17,352,000Source | -12,745,000Source | -16,817,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -8,000Source | -298,000Source | — | 791,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 8,000Source | 298,000Source | — | 18,000Source |
| Cash flows from financing activities: | ||||
| Payments for Repurchase of Common StockUSD | 3,190,000Source | — | — | — |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 10,648,000Source | 36,792,000Source | 10,995,000Source | -1,311,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | -17,337,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 14,700,000Source | 19,500,000Source | — | 2,029,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 0Source | 423,000Source | 34,000Source | 85,000Source |
| Income Taxes Paid, NetUSD | — | 0Source | — | — |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | -113,000Source | — |
| Additional Financial Items | ||||
| Accretion ExpenseUSD | — | — | 166,000Source | — |
| Share-based Payment Arrangement, ExpenseUSD | — | — | — | 1,152,000Source |
| Financing Interest ExpenseUSD | — | — | — | 51,000Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | 757,000Source | -212,000Source | 133,000Source | -913,000Source |
| Foreign Currency Transaction Gain (Loss), UnrealizedUSD | -1,238,000Source | 126,000Source | 179,000Source | -450,000Source |
| Gain (Loss) on InvestmentsUSD | — | — | — | -115,000Source |
| Gain (Loss) on Sale of InvestmentsUSD | — | — | — | 1,780,000Source |
| General and Administrative ExpenseUSD | 6,324,000Source | 11,442,000Source | 10,026,000Source | 9,962,000Source |
| Impairment of Intangible Assets (Excluding Goodwill)USD | 0Source | 9,703,000Source | — | — |
| Impairment of Intangible Assets, Finite-livedUSD | — | — | — | 17,571Source |
| Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)USD | 0Source | 9,703,000Source | 0Source | 17,571,000Source |
| Income Tax Expense (Benefit)USD | 0Source | -381,000Source | 83,000Source | -1,521,000Source |
| InterestExpenseNonoperatingUSD | 185,000Source | 653,000Source | — | — |
| Investment Income, InterestUSD | 801,000Source | 533,000Source | 22,000Source | 30,000Source |
| Net Income (Loss) Attributable to ParentUSD | -11,231,000Source | -24,515,000Source | -11,901,000Source | -16,058,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -11,231,000Source | -25,154,000Source | -20,416,000Source | -16,058,000Source |
| Nonoperating Income (Expense)USD | 1,374,000Source | 2,345,000Source | 5,311,000Source | 16,884,000Source |
| Operating ExpensesUSD | 12,925,000Source | 27,241,000Source | 17,129,000Source | 34,463,000Source |
| Proceeds from Issuance of Common StockUSD | 11,143,000Source | 37,354,000Source | — | — |
| Revenue from Contract with Customer, Including Assessed TaxUSD | 320,000Source | — | — | — |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Operating Income (Loss)USD | -12,605,000Source | -27,241,000Source | -17,129,000Source | -34,463,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -11,231,000Source | -24,896,000Source | -11,818,000Source | — |
| Income Tax Expense (Benefit)USD | 0Source | -381,000Source | 83,000Source | -1,521,000Source |
| Net Income (Loss) Attributable to ParentUSD | -11,231,000Source | -24,515,000Source | -11,901,000Source | -16,058,000Source |
| Earnings Per Share, BasicUSD per share | -0.78Source | -15.65Source | -10.26Source | -2.21Source |
| Earnings Per Share, DilutedUSD per share | — | — | -10.26Source | -2.21Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 14,378,942Source | 1,606,989Source | 1,990,748Source | 9,527,111Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 1,990,748Source | 9,527,111Source |
| Interest Expense (non-operating)USD | 185,000Source | 653,000Source | — | — |
| Additional Financial Items | ||||
| Current Income Tax Expense (Benefit)USD | 0Source | 0Source | — | — |
| Depreciation, Depletion and Amortization, NonproductionUSD | — | — | 37,000Source | — |
| Financing Interest ExpenseUSD | — | — | — | 51,000Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | 757,000Source | -212,000Source | 133,000Source | -913,000Source |
| Gain (Loss) on InvestmentsUSD | — | — | — | -115,000Source |
| General and Administrative ExpenseUSD | 6,324,000Source | 11,442,000Source | 10,026,000Source | 9,962,000Source |
| Income (Loss) Attributable to Parent, before TaxUSD | — | — | — | -17,579,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | -5,562,000Source | -8,520,000Source | — | — |
| Interest ExpenseUSD | — | — | 498,000Source | 12,000Source |
| Interest Expense, DebtUSD | — | — | — | 106,000Source |
| Investment Income, InterestUSD | 801,000Source | 533,000Source | 22,000Source | 30,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -11,231,000Source | -25,154,000Source | -20,416,000Source | -16,058,000Source |
| Net Income (Loss) from Continuing Operations Available to Common Shareholders, BasicUSD | — | — | — | -21,052,000Source |
| Nonoperating Income (Expense)USD | 1,374,000Source | 2,345,000Source | 5,311,000Source | 16,884,000Source |
| Operating ExpensesUSD | 12,925,000Source | 27,241,000Source | 17,129,000Source | 34,463,000Source |
| Other ExpensesUSD | — | — | — | 200,000Source |
| Preferred Stock Dividends, Income Statement ImpactUSD | — | — | 123,000Source | 1,572,000Source |
| Research and Development ExpenseUSD | 6,601,000Source | 6,096,000Source | 7,103,000Source | 6,930,000Source |
| Revenue from Contract with Customer, Including Assessed TaxUSD | 320,000Source | — | — | — |
Offerings
Registration 333-293420
Filing attachments
ea030729801ex99-1.htm · 8-K · 2026-10-01
Exhibit 99.1 Allarity Provides Update on Key Recent Advances Solidifying Drug Response Predictor® to Drive Stenoparib’s Clinical Development - Recently awarded patents have solidified Allarity’s strategy to leverage DRP to ensure the commercial exclusivity of stenoparib TARPON SPRINGS, Fla., September 30, 2026 - Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121) - a differentiate…
Read attachment ↗ea030687301ex99-1.htm · 8-K · 2026-09-29
Exhibit 99.1 Allarity Therapeutics Expands Laboratory Capabilities to Include Proteomics and Cell Line Research - Expanded laboratory capabilities support deeper mechanism-of-action research for stenoparib - New proteomics and cell line capabilities will broaden Allarity’s research capabilities to enable external partnerships TARPON SPRINGS, Fla., September 28, 2026 - Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company ded…
Read attachment ↗ea030557001ex99-1.htm · 8-K · 2026-09-16
EX-99.1 2 ea030557001ex99-1.htm PRESS RELEASE, DATED SEPTEMBER 15, 2026 Exhibit 99.1 Allarity Therapeutics Granted Japanese Patent for Stenoparib DRP® Companion Diagnostic, Further Strengthening Stenoparib Development TARPON SPRINGS, Fla., September 15, 2026 - Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121) - a differentiated, dual PARP and WNT pathway inhibitor - today ann…
Read attachment ↗ea030540801ex99-1.htm · 8-K · 2026-09-14
EX-99.1 2 ea030540801ex99-1.htm PRESS RELEASE, DATED SEPTEMBER 11, 2026 Exhibit 99.1 Allarity Therapeutics Announces Strategic Capital Allocation for Filing of SPAC Registration Statement TARPON SPRINGS, Fla., September 11, 2026 - Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib - a differentiated dual PARP/Wnt pathway inhibitor using its proprietary DRP® technology, announced that …
Read attachment ↗ea030215701ex99-1.htm · 8-K · 2026-08-14
EX-99.1 2 ea030215701ex99-1.htm PRESS RELEASE, DATED JUNE 30, 2026 Exhibit 99.1 Allarity Therapeutics Reports Second Quarter 2026 Results and Completion of the Phase 3-Ready Stenoparib Manufacturing Campaign - Completed quarter with $26.9 million in cash and restricted cash - Key U.S. patent was awarded, protecting exclusivity of stenoparib when used with the stenoparib-specific DRP ® companion diagnostic into 2042 - AACR 2026 data linked higher stenoparib DRP ® scores with enhanced over…
Read attachment ↗ea029661501ex99-1.htm · 8-K · 2026-07-01
EX-99.1 2 ea029661501ex99-1.htm PRESS RELEASE, DATED JUNE 30, 2026 Exhibit 99.1 Allarity Therapeutics Announces the Grant of Essential U.S. Patent for Its Stenoparib DRP® Companion Diagnostic Key U.S. patent now protects exclusivity for developing stenoparib with the stenoparib-DRP® until April 2042 ─────────────────────────────────────────────────────────── TARPON SPRINGS, Fla., June 30, 2026 - Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clini…
Read attachment ↗